Youngsook Choi

TL;DR: Edoxaban is an attractive alternative to warfarin in patients at increased risk of falling, because it is associated with an even greater absolute reduction in severe bleeding events and mortality.

TL;DR: The correlation between dose, trough edoxaban level, and the risk of GIB risk suggests GIB is exposure-related, whereas surgery required to manage bleeding was less frequent with HD-ER and warfarin.

TL;DR: Among patients with AF receiving oral anticoagulation, bleeding, but not thromboembolic events, was increased in patients with liver disease, and a history of liver disease did not alter the relative efficacy and safety of edoxaban compared with warfarin.

TL;DR: Long-term treatment with pexidartinib has a predictable effect on hepatic aminotransferases and unpredictable risk of serious cholestatic or mixed liver injury, and this pooled analysis provides information to help form the basis for the treating physician's risk assessment for patients with TCGT.

TL;DR: In conclusion, edoxaban associated major bleeding events have a comparable clinical presentation and course to major bleeds with VKA in patients treated for venous thromboembolism in the Hokusai-VTE study and may assure physicians that it is safe to prescribe this medication.